(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | -1.9MM | -116% |
Operating Income | -139.9MM | +7% |
Operating Expenses | 138MM | - |
Net Income | -132.2MM | +8% |
R&D | 109MM | -4% |
G&A | 29MM | -1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Moderna and Intellia have declined in the double digits over the past year.
When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest potential payoffs. Many a fortune has been made after successful clinical results or a timely FDA approval for a new drug. Following a company’s progress from research to approval can be a life-changing way to invest. At the same time, biotech companies can fail during a clinical trial or get denied by the FDA. In the biotech sector, this type of failure can set a company back years or worse, send the
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks. Look at gene editing stocks, like CRISPR Therapeutics (NASDAQ:CRSP), for example. Several weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood. Inv
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment
The company's future will depend on its innovative qualities.
2024 could see the start of its first late-stage clinical trials.
The futures for these two beaten-down stocks could be brighter than their recent pasts.
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
The popular money manager added to these three existing positions on Monday following disappointing financial updates earlier this month.